| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 29,733 | 21,359 | 89,012 | 24,197 |
| Cost of license and royalty revenues | 5,725 | 5,209 | 3,436 | - |
| Research and development | 56,101 | 59,500 | 53,087 | 54,429 |
| Other operating expenses | - | - | - | 37 |
| General and administrative | 20,253 | 19,883 | 20,347 | 19,422 |
| Cost of goods and services sold, total | - | - | - | 12,387 |
| Other operating expenses | -65 | -45 | -15 | - |
| Total operating expenses | 82,144 | 84,637 | 76,885 | 86,275 |
| Loss from operations | -52,411 | -63,278 | 12,127 | -62,078 |
| Interest income from licensing | 19 | 21 | 25 | 25 |
| Investment income | 3,620 | 3,379 | 2,501 | 3,276 |
| Interest expense | 13,169 | 10,993 | 8,570 | 820 |
| Total other income (expense) | -9,530 | -7,593 | -6,044 | 2,481 |
| Net loss | -61,941 | -70,871 | 6,083 | -59,597 |
| Unrealized gain on available-for-sale securities, net | 98 | 12 | -21 | 1,684 |
| Total other comprehensive income | 98 | 12 | -21 | 1,684 |
| Comprehensive loss | -61,843 | -70,859 | 6,062 | -57,913 |
| Earnings per share, basic | -1.2 | -1.38 | 0.12 | -1.17 |
| Earnings per share, diluted | -1.2 | -1.38 | 0.12 | -1.17 |
| Weighted average number of shares outstanding, basic | 51,689,000 | 51,483,000 | 51,362,000 | 50,800,000 |
| Weighted average number of shares outstanding, diluted | 51,689,000 | 51,483,000 | 51,434,000 | 50,800,000 |
REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX)